Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | CNR1 | P21554 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.39 |
| ▸ | USP28 | Q96RU2 | 2/20 | 0.39 |
| ▸ | USP25 | Q9UHP3 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | GUSB | P08236 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1626418 | 0.86 | IGF1R (0.51) | TAAR1LMNAMAPTKDM4E | |
| SCHEMBL27597650 | 0.83 | SLC2A1 (0.44) | NPC1ALDH1A1MAPTHPGDRAB9A | |
| SCHEMBL6051268 | 0.83 | ALDH1A1 (0.43) | TAAR1LMNACNR1NPC1ALDH1A1 | |
| SCHEMBL6051264 | 0.83 | ALDH1A1 (0.43) | TAAR1LMNACNR1NPC1ALDH1A1 | |
| SCHEMBL25003859 | 0.81 | MEN1 (0.42) | LMNANPC1ALDH1A1MAPK1MAPT | |
| SCHEMBL7167652 | 0.80 | MAPT (0.37) | LMNANPC1ALDH1A1MAPK1MAPT | |
| SCHEMBL31026410 | 0.80 | KDM4E (0.47) | LMNANPC1ALDH1A1MAPTKDM4E | |
| SCHEMBL27597649 | 0.79 | ACHE (0.42) | NPC1ALDH1A1MAPK1HPGDRAB9A | |
| SCHEMBL29280753 | 0.77 | MAPT (0.45) | LMNANPC1ALDH1A1MAPK1MAPT | |
| SCHEMBL23876536 | 0.74 | IGF1R (0.54) | LMNAMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7141580-B2 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | PFIZER INC. (US) | 2006-11-28 | — | — | US | disclosed |
| US-20040181059-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | ASKAT INC. (JP) | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040181059-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | PTGS1, PTGS2, OPRM1 | TAAR1 2216/4885LMNA 2960/4885CNR1 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.